BioMarin Pharmaceutical (NASDAQ: BMRN) disclosed Wednesday August 26, 2026 additional detail on the previously-announced Alesta Therapeutics acquisition (definitive agreement announced August 21). Transaction value: $275 million. Alesta's lead asset ALE1: an oral hypophosphatasia (HPP) therapy in clinical development. Hypophosphatasia is a rare inherited metabolic disease caused by loss-of-function mutations in the ALPL gene encoding tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme required for bone mineralization and other biological processes; without adequate TNSALP activity, patients develop rickets, osteomalacia, seizures (in the severe perinatal form), and other complications. Commercial context: the currently-approved treatment is AstraZeneca / Alexion's Strensiq (asfotase alfa), a recombinant TNSALP-Fc fusion protein administered as three-times-weekly subcutaneous injection at a list price of approximately $1.5-2.0 million per adult patient per year. ALE1 would compete as a smaller-molecule oral format that could expand access to adult HPP patients where the injectable enzyme replacement has been less-broadly reimbursed by payers due to cost and administration burden concerns. The acquisition continues BioMarin's rare-disease portfolio expansion following the Amicus Therapeutics integration earlier in 2026 (which added GALAFOLD for Fabry disease and POMBILITI + OPFOLDA for late-onset Pompe disease) alongside Voxzogo (vosoritide, C-type natriuretic peptide analog for achondroplasia, on track for $1+ billion annual sales in 2026) and the broader enzyme-replacement franchise.
Barclays' Head of US Biopharma Equity Research Emily Field told CNBC Monday August 24, 2026 that the biotech mergers and acquisitions (M&A) freeze is over. Key drivers cited: capital markets reopening (drug startup IPOs have raised roughly $6 billion year-to-date, more than the combined total of the prior four years by this point), large-cap pharma buyers committing to more deals following a multi-year period of caution, and fresh oncology data extending the sector's value proposition beyond the weight-loss drug narrative that dominated 2024-2025. The commentary follows a rapid acceleration of biotech M&A activity through August: Samsung Biologics' pending $1.8 billion PolyPeptide Group AG all-cash tender offer (formal prospectus expected end of August), BioMarin Pharmaceutical's Alesta Therapeutics acquisition for ALE1 program (August 21), Tolerance Bio's $260 million exclusive license from NeoImmuneTech for NT-I7 (efineptakin alfa, long-acting IL-7 fusion protein, August 20), LEO Pharma's dersimelagon (MC1R agonist) acquisition from Mitsubishi Tanabe (August 18), and Hanmi Pharm's up-to-$2.3 billion HM17321 UCN2 licensing to Genentech announced the same Monday. The pattern suggests the M&A environment is now supportive for both mid-cap platform buyers (Samsung Biologics, LEO Pharma, BioMarin) and mega-cap oncology and metabolic-disease buyers (Roche/Genentech, Bristol Myers Squibb, Merck, Eli Lilly) actively pursuing deals. Field's commentary also notes that oncology data (particularly the Merck-Moderna intismeran Phase 3 melanoma win and Gilead Trodelvy+Keytruda EU authorization from the same week) has substantially reset investor expectations about the sector beyond obesity.
BioMarin Pharmaceutical (NASDAQ: BMRN) announced Friday August 21, 2026 a definitive agreement to acquire Dutch biotech Alesta Therapeutics to gain Alesta's lead clinical-stage asset ALE1. Financial terms of the transaction were not publicly disclosed. Alesta's ALE1 program is in clinical development; the specific mechanism and indication have not been fully disclosed in initial press coverage, and additional details are expected in the deal filing documents. The acquisition adds to BioMarin's rare-disease portfolio alongside VOXZOGO (vosoritide, C-type natriuretic peptide analog administered as daily subcutaneous injection for achondroplasia in pediatric patients; delivered Q2 2026 revenue of $253 million +14% YoY and is on track for $1+ billion annual sales as BioMarin's first blockbuster franchise), the newly-integrated Amicus Therapeutics assets (GALAFOLD migalastat oral chaperone for Fabry disease, POMBILITI + OPFOLDA cipaglucosidase alfa plus miglustat for late-onset Pompe disease), and the broader enzyme-replacement franchise (VIMIZIM, Naglazyme, Aldurazyme, Palynziq). The Alesta acquisition continues BioMarin's pattern of rare-disease portfolio expansion following the Amicus integration completed earlier in 2026 that added roughly $220 million in expected non-GAAP cost synergies by 2028 and non-GAAP diluted EPS accretion beginning 2027. BioMarin's strategy of building a diversified rare-disease commercial franchise across peptide analogs (Voxzogo), oral small-molecule chaperones (GALAFOLD), enzyme replacements (Palynziq, VIMIZIM, Naglazyme, Aldurazyme), and now Alesta's ALE1 program continues to differentiate the company from single-franchise rare-disease competitors.